Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?

2020 ◽  
Author(s):  
Amanda Pereira-Salgado ◽  
Edmond Michael Kwan ◽  
Ben Tran ◽  
Peter Gibbs ◽  
Johann De Bono ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Health Economic ◽  
Real World ◽  
Economic Implications ◽  
Treatment Sequencing

scholarly journals Health economic implications of postoperative complications following liver resection surgery: a systematic review

2019 ◽  
Vol 89 (12) ◽  
pp. 1561-1566
Author(s):  
Luka Cosic ◽  
Ronald Ma ◽  
Leonid Churilov ◽  
Mehrdad Nikfarjam ◽  
Christopher Christophi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Health Economic ◽  
Liver Resection ◽  
Postoperative Complications ◽  
Economic Implications

Veterans Affairs Prostate Cancer Treatment Sequencing (VAPCaTS): A Real-World Evidence Study of Men with Metastatic Prostate Cancer

2021 ◽  
Vol 8 (1) ◽  
pp. 112-118
Author(s):  
Stephen J. Freedland ◽  
Amanda M. De Hoedt ◽  
Maral DerSarkissian ◽  
Rose Chang ◽  
Ambika Satija ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Real World ◽  
Metastatic Prostate Cancer ◽  
Veterans Affairs ◽  
Prostate Cancer Treatment ◽  
Real World Evidence ◽  
Treatment Sequencing

Real world patterns of treatment sequencing in Canada for metastatic castrate-resistant prostate cancer.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 320-320
Author(s):  
Sebastien J. Hotte ◽  
Antonio Finelli ◽  
Shawn Malone ◽  
Bobby Shayegan ◽  
Alan I. So ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Targeted Therapy ◽  
Best Practices ◽  
Real World ◽  
Advanced Prostate Cancer ◽  
First Line ◽  
Online Questionnaire ◽  
Physician Practices ◽  
Research Education ◽  
Treatment Sequencing

320 Background: The Canadian GU Research Consortium (GURC) was recently established to bring advanced prostate cancer centres together to collaborate on research, education, and adoption of best practices. As an initial step to inform the work of the GURC, an electronic questionnaire was designed to assess management of advanced prostate cancer care in Canada and how prostate cancer treatments are sequenced in a real-world setting. Methods: A 59-item online questionnaire was developed by a multidisciplinary scientific committee to measure physician practices, patterns of care, treatment sequencing, and management of mCRPC. After pre-testing, the online questionnaire was sent to 93 urologists, uro-oncologists, medical oncologists, radiation oncologists, and general practitioner oncologists who are actively involved in the treatment of prostate cancer. Results: A total of 49 (53%) respondents completed the questionnaire between April 17, 2017 to May 17, 2017. Based on physician reports, the most frequently used treatment for first-line mCRPC was AR-targeted therapy (94%, n = 46 physicians) such as abiraterone acetate plus prednisone and enzalutamide. Among those 46 physicians, AR-targeted therapy was usually followed by docetaxel second-line therapy (57%, 31 physicians). The most common line 1 to line 3 treatment sequence for mCRPC was: AR-targeted therapy--Docetaxel--AR-targeted therapy (35%, 17 physicians), followed by AR-targeted therapy--Docetaxel--Radium 223 (14%, n = 7), Provincial differences were observed in the line 1 to line 3 treatment sequences, which aligned to variation in provincial policies for access to the treatments. In patients previously treated with docetaxel in the hormone sensitive setting, the most frequently used treatment for first-line mCRPC was AR-targeted therapy (76%, 37 physicians). Conclusions: AR targeted therapy followed by docetaxel is the predominant pattern of practice for management of mCRPC, with variability beyond these lines of therapy. Prospective ongoing work through the GURC in research, education and best practices will aim to understand these practice patterns.

scholarly journals Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review

2021 ◽  
Vol 27 ◽  
pp. 77-87
Author(s):  
Koen Degeling ◽  
Amanda Pereira-Salgado ◽  
Niall M. Corcoran ◽  
Paul C. Boutros ◽  
Peter Kuhn ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Health Economic ◽  
Economic Evidence ◽  
Molecular Tests ◽  
Prostate Biopsies
Sign in / Sign up

Export Citation Format

Share Document